All posts by: MarksMan Healthcare

About MarksMan Healthcare

MarksMan Healthcare Communications

Systematic reviews (SRs) often face a major challenge while identifying all the relevant research, including randomised controlled trials (RCTs) irrespective of their publication status.(1) Unpublished, selectively reported, or non-reported research can lead to poorer quality clinical trials, thus leading to suboptimal care delivery. It also overlooks the opportunities for potential scientific progress.(2) Such incomplete publication […]

Clinical practice should ideally rely on robust scientific evidence, the standard for which are systematic reviews and meta-analyses of all randomised controlled trials (RCTs). (1,2) Therapeutic decisions in healthcare must be informed by clinical research findings, and patients and prescribers must be able to trust the presented research evidence. However, this evidence can be considered […]

Systematic reviews (SRs) are crucial in health and scientific research as they offer a thorough understanding of the findings from research. (1) They provide critical information on different aspects of research, such as answers to the questions not often addressed by individual studies, problems in primary research that need to be avoided in future studies, […]

In a data-driven world, where everything can be digitalized, drug regulators and sponsors are increasingly looking beyond the confines of clinical trials. The use of real-world data (RWD) is becoming common in the clinical development process of a drug. RWD enhances the drug approval process, helps sponsors understand how a particular intervention really performs, and […]

Systematic reviews (SRs) are incredibly crucial for healthcare decision-making, as they often provide a reliable summary of evidence on the comparison among healthcare interventions. They identify, assess, and combine the results of similar but individual studies and help to clarify the known and unknown benefits and risks associated with drugs, devices, and other healthcare interventions. […]

The need for transparency in drug pricing is getting severe with increased spending on medications with each passing year. Drug spending in the US, without the discounts, has been reported to be $309.5 billion in the year 2015, which is about 8.5% higher than that reported in the preceding year. (1) As a result, undoubtedly, […]

Health utilities are cardinal values in identifying an individual’s preference for different health outcomes. Health utilities are transformed to Quality Adjusted Life Years (QALYs) to enable comparisons between health interventions in cost-utility analysis in Pharmacoeconomics. Health utilities are measured using various utility ‘instruments’, which can be either generic (that is, can be applied to all […]